Complete response to erlotinib and bevacizumab in a patient with Biphenotypic (hepatobiliary) primary liver carcinoma

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Biphenotypic (hepatobiliary) primary liver carcinomas [B(H-B)PLCs] are rare tumors with features of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). These tumors are associated with a poor overall prognosis and treatment is not well defined. Research over the past 20 years has identified aberrations in several molecular pathways, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in hepatocellular and biliary tract cancers. These discoveries led to the evaluation of targeted therapies, such as tyrosine kinase inhibitors, for the treatment of HCC and ICC. We report a case of a patient with metastatic B(H-B)PLC found to have a single nucleotide variant in the EGFR gene locus R521K who achieved a complete response on imaging after treatment with the combination of an EGFR inhibitor and a VEGF inhibitor. This case prompts consideration of further genomic analysis of these rare tumors and the potential use of targeted therapies in the treatment of patients with B(H-B)PLCs.

Original languageEnglish
Pages (from-to)1468-1473
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint Dive into the research topics of 'Complete response to erlotinib and bevacizumab in a patient with Biphenotypic (hepatobiliary) primary liver carcinoma'. Together they form a unique fingerprint.

  • Cite this